Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Sells Human Stem Cell Subsidiary to Takara Bio

NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.

The sale is the final step in Cellectis' restructuring of its Tools and Services business unit, which it said had been incurring heavy losses. The unit had an operating loss of €14 million ($18.8 million) in 2013 before accounting for extraordinary depreciation and costs related to downsizing.

Cellectis AB focuses on applications of human embryonic stem cell-based products and technologies for the research market and industry. Cellectis said the sale is expected to result in a loss of about €5 million. It added that the deal, expected to be completed in the coming weeks, will allow it to concentrate on its immunotherapy products for cancer applications.

Takara Bio is a Japanese biotechnology firm focused on gene therapies, genetic engineering, and provides research tools for molecular biology, cell biology, and protein research.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.